Cost-Effectiveness Analysis of Peginterferon Beta-1a In Italian Relapsing Remitting Multiple Sclerosis Management

Abstract

to disability progression rate. ConClusions: The incremental cost effectiveness ratio of 17.433 € is considerably below the threshold usually accepted for financing medicines in Portugal (around 30.000 € /QALY). Dimethyl Fumarate should be seen as a cost-effective therapy for the Portuguese setting. PND57Cost-EffECtivENEss ANAlysis of PEgiNtErfEroN BEtA-1A iN itAliAN rElAPsiNg rEmittiNg multiPlE sClErosis mANAgEmENt

Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis

“…Studies on peginterferon beta-1a have been conducted in the United States, Italy, Ireland, and Scotland and have compared peginterferon beta-1a to multiple comparators over 10 years to lifetime analytic time frames using societal and payer perspectives. [7][8][9][10][11] Studies on alemtuzumab have been conducted in the Unites States, Ireland, and the United Kingdom using societal and payer perspectives and have used 2-to 10-year analytic time frames. [12][13][14] Both U.S.-based studies on peginteferon beta-1a used a payer perspective and an analytical time frame of 10 years.…”

The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in Italy

“…Several works assessed the cost-effectiveness of DMTs from the Italian perspective; [65][66][67] however, none assessed long-term effects and costs of alemtuzumab in RRMS patients. Dashputre et al 68 and Montgomery et al 69 assessed alemtuzumab among other DMTs from the perspective of the third-party payer in the United States and the perspective of the National Health Service in the United Kingdom.…”